Site-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus
-
Coronary Artery Disease (CAD)
-
Catheterization & Cardiovascular Interventions (CCI)
